Unique Pharmaceutical Laboratories Profile
Key Indicators
- Authorised Capital ₹ 7.00 Cr
as on 23-06-2024
- Paid Up Capital ₹ 0.75 M
as on 23-06-2024
- Company Age 52 Year, 8 Months
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 4.61 Cr
as on 23-06-2024
- Revenue -88.05%
(FY 2021)
- Profit -91.50%
(FY 2021)
- Ebitda -105.31%
(FY 2021)
- Net Worth 4.21%
(FY 2021)
- Total Assets 1.22%
(FY 2021)
About Unique Pharmaceutical Laboratories
The Company is engaged in the Financial Services Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 7.00 Cr and a paid-up capital of Rs 0.75 M.
The company currently has active open charges totaling ₹4.61 Cr.
Jay Mehta, Bharat Mehta, and Kushal Dalal serve as directors at the Company.
- CIN/LLPIN
U24239MH1972PLC015744
- Company No.
015744
- Company Classification
Public Limited Indian Non-Government Company
- Incorporation Date
11 Apr 1972
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Mumbai
Industry
Company Details
- Location
Mumbai, Maharashtra, India
- Telephone
- Email Address
- Website
- Social Media-
Who are the key members and board of directors at Unique Pharmaceutical Laboratories?
Board Members(3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Kushal Dalal  | Director | 23-Dec-2020 | Current |
| Jay Mehta | Director | 13-Mar-2006 | Current |
| Bharat Mehta | Director | 17-Jan-1981 | Current |
Financial Performance and Corporate Structure Insights of Unique Pharmaceutical Laboratories.
Unique Pharmaceutical Laboratories Limited, for the financial year ended 2021, experienced significant reduction in revenue, with a 88.05% decrease. The company also saw a substantial fall in profitability, with a 91.5% decrease in profit. The company's net worth moved up by a moderate rise of 4.21%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations | |||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Unique Pharmaceutical Laboratories?
In 2021, Unique Pharmaceutical Laboratories had a promoter holding of 38.27% and a public holding of 61.73%. The company had 1 Associate company. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Gujrat Industrial Investment Corporation Ltd Creation Date: 06 Jun 1994 | ₹5.90 M | Open |
Gujrat Industrial Investment Corporation Ltd Creation Date: 25 Nov 1991 | ₹9.80 M | Open |
Gujrat Industrial Investment Corporation Ltd Creation Date: 30 Jan 1990 | ₹6.80 M | Open |
How Many Employees Work at Unique Pharmaceutical Laboratories?
Unlock and access historical data on people associated with Unique Pharmaceutical Laboratories, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Unique Pharmaceutical Laboratories, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Unique Pharmaceutical Laboratories's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
